Local delivery of osteoprotegerin may be a way of reinforcing orthodontic anchorage

Medical Hypotheses

Volumn 72, Issue 2, 2009, Pages 178-179

  Li, Yongming ^a   Tang, Lin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANTIGEN EXPRESSION; ARTICLE; BONE REMODELING; CELL ACTIVATION; HUMAN; ORTHODONTICS; OSTEOLYSIS; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION;

HUMANS; ORTHODONTIC ANCHORAGE PROCEDURES; OSTEOPROTEGERIN; TOOTH MIGRATION;

EID: 57749178174     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.09.022     Document Type: Article

References (12)

1. Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5 (2005) 618-625
2. Hofbauer L.C., and Heufelder A.E. Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med 79 (2001) 243-253
3. Takahashi N., Udagawa N., and Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256 (1999) 449-455
4. Tang L, Li YM, Lin Z. Effects of different magnitudes mechanical strain on osteoblasts in vitro. Biochem Biophys Res Commun 2006; 344: 122-128.
5. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16 (2001) 348-360
6. Body J.-.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.-.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
7. Capparelli C., Morony S., Warmington K., Adamu S., Lacey D.L., Dunstan C.R., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18 (2003) 852-858
8. Kostenuik P.J., Bolon B., Morony S., Daris M., Geng Z., Carter C., et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 34 (2004) 656-664
9. Morony S., Capparelli C., Lee R., Shimamoto G., Boone T., Lacey D.L., et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 14 (1999) 1478-1485
10. Schett G., Redlich K., Hayer S., Zwerina J., Bolon B., Dunstan C.R., et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48 (2003) 2042-2051
11. Teng Y.-.T.A., Nguyen H.Q., Gao X., Kong Y.-.K., Gorczynski R.M., Singh B., et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 106 (2000) R59-67
12. Shiotani A., Shibasaki Y., and Sasaki T. Localization of receptor activator of NFkappaB ligand, RANKL, in periodontal tissues during experimental movement of rat molars. J Electron Microsc (Tokyo) 50 (2001) 365-369